AERI earnings call for the period ending March 31, 2019.
News & Analysis: Aerie Pharmaceuticals
AERI earnings call for the period ending December 31, 2018.
The company's establishing itself as a leader in this growing, multibillion-dollar indication.
The company's glaucoma treatment has gotten the regulatory green light, but can it live up to lofty expectations?
These stocks led the market to record highs. Find out why.
Investors cheer the release of upbeat clinical results from an important phase 3 trial.
Axovant Sciences, Esperion Therapeutics, and Aerie Pharmaceuticals are developing drugs targeting multibillion-dollar indications.
Aerie Pharmaceuticals' potential to revolutionize glaucoma treatment could lead to blockbuster sales one day.
Aerie Pharmaceuticals, Flexion Therapeutics, and Puma Biotechnology may have more running room ahead if regulators give their drugs the go-ahead.
Shares are spiking after Wall Street analysts issue "buy" ratings.